You are here:
Translational Immunology Section
The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting edge immune monitoring technology that will be made available to all NIAMS investigators.
Through the TIS, NIAMS researchers will be provided with services, consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient. The TIS boasts state-of-the-art immunoassays such as multicolor flow cytometry and Luminex, which will allow NIAMS clinicians to monitor the immune responses of their clinical trial patients. Analysis of a reference population to define baseline responses will allow for quality control checks that will validate the reproducibility of these results.
Jesus AA, Osman M, Silva CA, Kim PW, Pham TH, Gadina M, Yang B, Bertola DR, Carneiro-Sampaio M, Ferguson PJ, Renshaw BR, Schooley K, Brown M, Al-Dosari A, Al-Alami J, Sims JE, Goldbach-Mansky R, El-Shanti H. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum. 2011 Dec;63(12):4007-17. doi: 10.1002/art.30588.
Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, Labranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
Yang B, Hang-Pham T, Goldbach-Mansky R, Gadina M. Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay.J Vis Exp. 2011 Mar 1;(49). pii: 2662. doi: 10.3791/2662.
Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WE, Cho YH, Bang D, O'Shea J, Wallace GR, Gadina M, Kastner DL, Gül A. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet. 2010 Aug;42(8):698-702.
Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgċrd U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009 Jun 4;360(23):2426-37.
Burrows JF, Kelvin AA, McFarlane C, Burden RE, McGrattan MJ, De la Vega M, Govender U, Quinn DJ, Dib K, Gadina M, Scott CJ, Johnston JA. USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. J Biol Chem. 2009 Apr 3;284(14):9587-95. Epub 2009 Feb 2.PMID: 19188362See extended list of publications
Reviewed September 24, 2012